Drug intelligence / Profile preview

AR044

Development stage: Preclinical
Lead developer: Y Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

AR044 is a monoclonal antibody being developed by Y Biologics for the treatment of solid tumors. It specifically targets Immunoglobulin Superfamily Member 1 (IGSF1), a plasma membrane glycoprotein. The drug is currently in the IND-enabling stage, which involves the final preclinical studies required to support an Investigational New Drug (IND) application. While the exact functional mechanism—whether it acts as an antagonist or through another pathway—has not been explicitly detailed in public disclosures, the antibody is designed to leverage IGSF1 as a therapeutic target in the oncology setting.

Targets

IGSF1 (Immunoglobulin superfamily member 1)

Beyond the preview

Go deeper on AR044.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AR044.

Explore the full profile